Search results
Former Pfizer Worker’s 401(k) Account Won’t Be Given to Ex-Wife
Bloomberg Law· 21 hours agoemployee can’t access his 401(k) account to satisfy a $75,000 judgment against him in a defamation lawsuit, a Pennsylvania federal judge said. Judge Juan R. Sánchez rejected her request with ...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 3 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 3 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 3 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 2 days agoWho should wait, and who should get vaccinated now? The CDC advises that everyone ages 5 and older...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails -...
Benzinga· 17 hours agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo Finance· 5 days agoPfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 2 days agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Is this the Time to Initiate a Pfizer (PFE) Position?
Insider Monkey via Yahoo Finance· 4 days agoDiamond Hill Capital, an investment management company, released its “Select Strategy” first-quarter...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 2 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...